Balance Sheet
Cash Flow Statement
Change in Account PayablesChange in TaxesOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Capital Expenditures (2018 - 2022)

Historic Capital Expenditures for China SXT Pharmaceuticals (SXTC) over the last 5 years, with Q3 2022 value amounting to $343153.0.

  • China SXT Pharmaceuticals' Capital Expenditures fell 429.93% to $343153.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $343153.0, marking a year-over-year decrease of 429.93%. This contributed to the annual value of $363078.0 for FY2022, which is 209.89% up from last year.
  • According to the latest figures from Q3 2022, China SXT Pharmaceuticals' Capital Expenditures is $343153.0, which was down 429.93% from $363078.0 recorded in Q1 2022.
  • Over the past 5 years, China SXT Pharmaceuticals' Capital Expenditures peaked at $649235.0 during Q1 2019, and registered a low of $180000.0 during Q3 2019.
  • Over the past 5 years, China SXT Pharmaceuticals' median Capital Expenditures value was $360823.5 (recorded in 2021), while the average stood at $422670.0.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Capital Expenditures plummeted by 6857.6% in 2019, and later surged by 14970.22% in 2020.
  • Over the past 5 years, China SXT Pharmaceuticals' Capital Expenditures (Quarter) stood at $572811.0 in 2018, then plummeted by 68.58% to $180000.0 in 2019, then surged by 149.7% to $449464.0 in 2020, then fell by 20.22% to $358569.0 in 2021, then dropped by 4.3% to $343153.0 in 2022.
  • Its Capital Expenditures was $343153.0 in Q3 2022, compared to $363078.0 in Q1 2022 and $358569.0 in Q3 2021.